Wim Demey

2.7k total citations
17 papers, 316 citations indexed

About

Wim Demey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Wim Demey has authored 17 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Wim Demey's work include Bladder and Urothelial Cancer Treatments (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Wim Demey is often cited by papers focused on Bladder and Urothelial Cancer Treatments (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Wim Demey collaborates with scholars based in Belgium, United States and United Kingdom. Wim Demey's co-authors include Daniël Knockaert, Herman Bobbaers, Daniël Blockmans, Steven Vanderschueren, Anne Durnez, Tom Adriaenssens, Yohann Loriot, Siniša Radulović, Daniel P. Petrylak and Se Hoon Park and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

Wim Demey

13 papers receiving 306 citations

Peers

Countries citing papers authored by Wim Demey

Since Specialization

Citations

This map shows the geographic impact of Wim Demey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim Demey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim Demey more than expected).

Fields of papers citing papers by Wim Demey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim Demey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim Demey. The network helps show where Wim Demey may publish in the future.

Co-authorship network of co-authors of Wim Demey

This figure shows the co-authorship network connecting the top 25 collaborators of Wim Demey. A scholar is included among the top collaborators of Wim Demey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim Demey. Wim Demey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO). 2025 ·BMC Cancer ·(unknown), Timon Vandamme, Geert Roeyen, Dries Reynders, Wim Demey, Karin Stellamans, Barbara Bussels, (unknown), (unknown), Christelle Bouchart, Maaike Berbée, François Lallemand, (unknown), Mélissa Thomas, (unknown), (unknown), (unknown), (unknown), Reinhilde Weytjens, Ines Joye	0
2	PD37-12 AVELUMAB FIRST-LINE MAINTENANCE IN ADVANCED UROTHELIAL CARCINOMA: CONDITIONAL SURVIVAL AND LONG-TERM SAFETY IN PATIENTS TREATED FOR ≥1 OR ≥2 YEARS IN JAVELIN BLADDER 100 2025 ·The Journal of Urology ·Petros Grivas, Se Hoon Park, Éric Voog, Wen‐Pin Su, Wim Demey, Peter C.C. Fong, (unknown), Aslihan Gerhold‐Ay, (unknown), (unknown), Joaquim Bellmunt, Thomas Powles	0
3	1975P Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100 2024 ·Annals of Oncology ·(unknown), S.H. Park, Éric Voog, (unknown), Wim Demey, Peter C.C. Fong, J. Garcia, (unknown), Aslihan Gerhold‐Ay, (unknown), (unknown), (unknown), (unknown)	1
4	NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer 2023 ·Clinical Cancer Research ·(unknown), Greetje Vanhoutte, Willem Lybaert, Wim Demey, Jochen Decaestecker, (unknown), (unknown), Karen Zwaenepoel, Patrick Pauwels, Erik Fransén, Ken Op de Beeck, Guy Van Camp, Christian Rolfo, Marc Peeters	12
5	181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative 2023 ·Annals of Oncology ·Philippe Aftimos, Kevin Punie, Lore Decoster, Cédric van Marcke, Aline Hébrant, Gordana Raicevic, Els Van Valckenborgh, Brigitte Maes, (unknown), Joëlle Collignon, (unknown), (unknown), Wim Demey, Sabine Tejpar, Marc Peeters, J-L. Canon, Willem Lybaert, Jeroen Mebis, Sylvie Rottey, Jacques De Grève	0
6	Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur) 2021 ·Acta Clinica Belgica ·(unknown), Ivan Borbath, Marc Van den Eynde, (unknown), Wim Demey, Alain Verstraete, Kathleen Claes, Vincent Haufroid, Karen Geboes	11
7	468P PANIB 20139173: Randomized, multicentre phase II trial comparing fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus panitumumab versus FOLFOX plus bevacizumab in patients with previously untreated, RAS wild-type (WT) metastatic colorectal cancer (mCRC) 2020 ·Annals of Oncology ·Katrien Janssens, Erik Fransén, Christian Rolfo, Willem Lybaert, Wim Demey, Jochen Decaestecker, Koen Hendrickx, (unknown), Ken Op de Beeck, Guy Van Camp, Marc Peeters	2
8	704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 2020 ·Annals of Oncology ·Petros Grivas, S.H. Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Shilpa Gupta, Bo Huang, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Thomas Powles	10
9	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. 2020 ·Journal of Clinical Oncology ·Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Alessandra di Pietro, Petros Grivas	55
10	Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program 2019 ·Journal of Geriatric Oncology ·Sofie Joris, Thierry Pieters, Anne Sibille, F. Bustin, (unknown), (unknown), Veerle Surmont, Jean‐Charles Goeminne, (unknown), (unknown), Wim Demey, (unknown), (unknown), Stéphane Holbrechts, Denis Schallier, Lore Decoster	9
11	Impact of NET MDT on overall survival within NETwerk, a collaborative ENETS Center of Excellence. 2018 ·Journal of Clinical Oncology ·Timon Vandamme, (unknown), (unknown), Pascale Abrams, Ann Driessen, Bart Op de Beeck, Wim Demey, (unknown), (unknown), Geert Roeyen, Willem Lybaert, Marc Peeters	0
12	Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial) 2018 ·Annals of Oncology ·Hubert Piessevaux, Wim Demey, Alain Bols, Jozef Janssens, Marc Polus, (unknown), Stéphanie Laurent, Anne Demols, Yves Humblet, (unknown), (unknown), Michel Ferrante, Els Monsaert, (unknown), Jean‐Luc Van Laethem, Sabine Tejpar	1
13	Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. 2017 ·Journal of Clinical Oncology ·Bram De Laere, Peter Van Oyen, Christophe Ghysel, Piet Ost, Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, Willem Lybaert, Els Everaert, J Ampe, (unknown), Daan De Maeseneer, (unknown), Alain Bols, Karen Fransis, Gert Van den Eynden, J. Vandebroek, Steven Van Laere, Luc Dirix	2
14	Recurrent Low- to Intermediate-Grade Chondrosarcoma of the Thumb with Lung Metastases: An Objective Response to Trofosfamide 2007 ·Oncology Research and Treatment ·Philip R. Debruyne, Herlinde Dumez, Wim Demey, (unknown), Raf Sciot, Patrick Schöffski	5
15	Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer 2007 ·Breast Cancer Research and Treatment ·Toon Maes, Hans Wildiers, Sam Heye, Wim Demey, Geert Maleux, Patrick Neven, Allan T. van Oosterom, Robert Paridaens	12
16	From Prolonged Febrile Illness to Fever of Unknown Origin 2003 ·Archives of Internal Medicine ·Steven Vanderschueren, Daniël Knockaert, Tom Adriaenssens, Wim Demey, Anne Durnez, Daniël Blockmans, Herman Bobbaers	185
17	From prolonged febrile illness to fever of unknown origin. The challenge continues 2002 ·Clinical Microbiology and Infection ·Steven Vanderschueren, Daniël Knockaert, Tom Adriaenssens, Wim Demey, (unknown), Daniël Blockmans, Herman Bobbaers	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact